Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000480097 | SCV000572440 | uncertain significance | not provided | 2016-12-06 | criteria provided, single submitter | clinical testing | This variant is denoted BRCA2 c.7568T>C at the cDNA level, p.Leu2523Pro (L2523P) at the protein level, and results in the change of a Leucine to a Proline (CTG>CCG). Using alternate nomenclature, this variant would be defined as BRCA2 7796T>C. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Leu2523Pro was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Leucine and Proline differ in some properties, this is considered a semi-conservative amino acid substitution. BRCA2 Leu2523Pro occurs at a position that is conserved across species and is located within the FANCD2, SHFM1, DSS1, and DNA binding domains (Marston 1999, Yang 2002, UniProt). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA2 Leu2523Pro is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. |